OPDIVO is a prescription medicine used in combination with YERVOY as a first treatment to treat adults with cancer of the ...

Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024.

Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants ...

In the new subcutaneous drug delivery landscape, the growing trend towards patient-friendly, at-home administration is ...

Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease: Thousand Oaks, California Wednesday, April 8 ...

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.

Amgen has announced positive topline findings from a phase 3 study evaluating a subcutaneous formulation of Tepezza in adults with moderate to severe active thyroid eye disease (T ...

Amgen Inc. (NASDAQ:AMGN) is one of the 7 Most Profitable Value Stocks to Buy Right Now. Amgen Inc. (NASDAQ:AMGN) is one of ...

The tumor begins before birth. Somewhere in the developing fetus, neural crest cells that should have matured into adrenal tissue or sympathetic ganglia take a wrong turn, and a child is born ...

Eli Lilly and Company LLY, last week, gained the much-anticipated FDA approval for its once-daily oral GLP-1 pill ...

Neuroblastoma kills more children under one year of age than any other extracranial solid tumor, and high-risk cases have ...